Internal Medicine, Hematology & Oncology · Flemington, NJ
NPI
1235127622
Since 2005
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
2100 Wescott Dr
Flemington, NJ, 08822
Phone (908) 788-6461
Groups this clinician bills Medicare through
Medicare paid, 2024
$5.1M
393,401 services
Medicare patients, 2024
767
Average age 75
Drug cost, 2024
$14.0M
2,792 prescriptions
Company payments, 2025
$2,149
From 42 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Myron E Bednar was code J1439 (injection, ferric carboxymaltose, 1 mg), 81,003 times for 61 patients. In total Myron E Bednar billed 393,401 services in 173 codes, and Medicare paid $5.1M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2013-02-22.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 81,003 | 61 | $0.87 | $71K |
| J0897 Injection, denosumab, 1 mg | Office | 24,313 | 117 | $20.57 | $500K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 14,072 | 23 | $8.17 | $115K |
| J0185 Injection, aprepitant, 1 mg | Office | 13,520 | 36 | $1.35 | $18K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 8,387 | 33 | $20.82 | $175K |
| J1568 Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | Office | 7,864 | 23 | $36.98 | $291K |
| J1627 Injection, granisetron, extended-release, 0.1 mg | Office | 6,901 | 27 | $4.39 | $30K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 5,984 | 43 | $6.18 | $37K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 3,230 | 15 | $35.92 | $116K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 2,840 | 68 | $0.09 | $256 |
| 85025 Blood Count | Office | 2,516 | 572 | $7.61 | $19K |
| J9395 Injection, fulvestrant, 25 mg | Office | 1,857 | 12 | $6.21 | $12K |
| 96372 Injection Administration | Office | 1,563 | 263 | $12.27 | $19K |
| 80053 Clinical Chemistry | Office | 1,338 | 480 | $10.35 | $14K |
| 83615 Clinical Chemistry | Office | 1,319 | 470 | $5.92 | $7,808 |
By year: 2022 $5.6M for 371,647 services; 2023 $4.8M for 373,747 services; 2024 $5.1M for 393,401 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 2,516 | 572 | $7.61 | $19K |
| 80053 Clinical Chemistry | 1,338 | 480 | $10.35 | $14K |
| 83615 Clinical Chemistry | 1,319 | 470 | $5.92 | $7,808 |
| 36415 Venipuncture Blood Collection | 867 | 422 | $8.65 | $7,500 |
| 83735 Clinical Chemistry | 719 | 285 | $6.57 | $4,724 |
| 84100 Clinical Chemistry | 713 | 283 | $4.65 | $3,315 |
| 86300 Immunoassay | 261 | 115 | $20.39 | $5,322 |
| 82306 Clinical Chemistry | 222 | 139 | $29.01 | $6,440 |
| 84443 Clinical Chemistry | 145 | 70 | $16.46 | $2,387 |
| 84439 Clinical Chemistry | 142 | 68 | $8.84 | $1,255 |
Medicare prescription drug claims, 2024
In 2024, the drug Myron E Bednar prescribed most often to Medicare patients was Procrit (Epoetin Alfa), with 158 prescriptions and refills. In total Myron E Bednar wrote 2,792 Medicare prescriptions that cost $14.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Procrit Epoetin Alfa | 158 | 158 | 41 | $646K |
| Anastrozole Generic | 135 | 377 | 42 | $3,375 |
| Prednisone Generic | 110 | 138 | 36 | $581 |
| Abiraterone Acetate Generic | 101 | 101 | 11 | $214K |
| Eliquis Apixaban | 78 | 143 | 21 | $80K |
| Lenalidomide Generic | 66 | 66 | Under 11 | $898K |
| Erleada Apalutamide | 63 | 63 | Under 11 | $889K |
| Revlimid Lenalidomide | 63 | 63 | 15 | $1.2M |
| Calquence Acalabrutinib Maleate | 55 | 55 | Under 11 | $831K |
| Lupron Depot Leuprolide Acetate | 51 | 167 | 18 | $336K |
| Xgeva Denosumab | 50 | 70 | 11 | $157K |
| Acyclovir Generic | 50 | 116 | 12 | $1,213 |
| Zarxio Filgrastim-Sndz | 47 | 47 | 12 | $116K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 45 | 45 | Under 11 | $429K |
| Dexamethasone Generic | 43 | 73 | 24 | $1,002 |
Brand drugs: - claims; generic drugs: 1,400 claims; opioid claims: 45.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Myron E Bednar $2,149 ($2,149 in general payments such as food, travel and fees) from 42 companies. The largest payer was Daiichi Sankyo Inc. with $259.
| Company | Payments | Amount |
|---|---|---|
| Daiichi Sankyo Inc. 4568.T | 10 | $259 |
| Sobi, Inc SOBI.ST | 3 | $210 |
| Gilead Sciences, Inc. GILD | 11 | $156 |
| Pfizer Inc. PFE | 7 | $151 |
| Novartis Pharmaceuticals Corporation NVS | 7 | $126 |
| E.R. Squibb & Sons, L.L.C. BMY | 6 | $105 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $96.1 |
| GlaxoSmithKline, LLC. GSK | 4 | $81.93 |
| Genzyme Corporation SNY | 4 | $78.8 |
| Regeneron Healthcare Solutions, Inc. REGN | 3 | $78.03 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.